AmacaThera Analysis: $15M Raised
What is AmacaThera?
Injectable hydrogel platform for drug delivery
Location
Toronto, Canada
Employees
1-10
Founded
2016
Product Features & Capabilities
- Injectable hydrogel platform
- AMT-143 for non-opioid pain management
- Advanced sustained release formulations
Use Cases
Administer localized drug delivery for post-surgical pain; Evaluate AMT-143 in human studies; Develop formulations for cancer treatment; Provide sustained release of therapeutics; Collaborate with partners for drug development
Other Considerations
Closed CAD$4.0 million Series A extension; Exclusive global licensing agreement with Pacira BioSciences; Dosed first human subject with AMT-143; Featured in RBCx media coverage
See something that needs updating? Suggest edits to this profile.